GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009719310 | Cervix | CC | intrinsic apoptotic signaling pathway | 85/2311 | 288/18723 | 4.56e-15 | 6.46e-12 | 85 |
GO:200123310 | Cervix | CC | regulation of apoptotic signaling pathway | 96/2311 | 356/18723 | 4.08e-14 | 3.05e-11 | 96 |
GO:200124210 | Cervix | CC | regulation of intrinsic apoptotic signaling pathway | 52/2311 | 164/18723 | 5.06e-11 | 1.01e-08 | 52 |
GO:00603267 | Cervix | CC | cell chemotaxis | 73/2311 | 310/18723 | 2.82e-08 | 1.96e-06 | 73 |
GO:200123410 | Cervix | CC | negative regulation of apoptotic signaling pathway | 56/2311 | 224/18723 | 1.39e-07 | 6.70e-06 | 56 |
GO:200124310 | Cervix | CC | negative regulation of intrinsic apoptotic signaling pathway | 28/2311 | 98/18723 | 1.31e-05 | 2.66e-04 | 28 |
GO:00068987 | Cervix | CC | receptor-mediated endocytosis | 53/2311 | 244/18723 | 2.52e-05 | 4.29e-04 | 53 |
GO:00434104 | Cervix | CC | positive regulation of MAPK cascade | 90/2311 | 480/18723 | 2.92e-05 | 4.83e-04 | 90 |
GO:20010209 | Cervix | CC | regulation of response to DNA damage stimulus | 46/2311 | 219/18723 | 1.92e-04 | 2.23e-03 | 46 |
GO:00015704 | Cervix | CC | vasculogenesis | 22/2311 | 80/18723 | 1.97e-04 | 2.26e-03 | 22 |
GO:00431127 | Cervix | CC | receptor metabolic process | 37/2311 | 166/18723 | 2.31e-04 | 2.58e-03 | 37 |
GO:00192213 | Cervix | CC | cytokine-mediated signaling pathway | 84/2311 | 472/18723 | 3.25e-04 | 3.44e-03 | 84 |
GO:00086309 | Cervix | CC | intrinsic apoptotic signaling pathway in response to DNA damage | 24/2311 | 99/18723 | 7.93e-04 | 6.99e-03 | 24 |
GO:19022294 | Cervix | CC | regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 12/2311 | 36/18723 | 8.74e-04 | 7.58e-03 | 12 |
GO:00703714 | Cervix | CC | ERK1 and ERK2 cascade | 60/2311 | 330/18723 | 1.28e-03 | 1.02e-02 | 60 |
GO:00703723 | Cervix | CC | regulation of ERK1 and ERK2 cascade | 54/2311 | 309/18723 | 5.11e-03 | 3.02e-02 | 54 |
GO:00316236 | Cervix | CC | receptor internalization | 24/2311 | 113/18723 | 5.18e-03 | 3.05e-02 | 24 |
GO:0097193111 | Esophagus | ESCC | intrinsic apoptotic signaling pathway | 222/8552 | 288/18723 | 5.87e-28 | 2.02e-25 | 222 |
GO:2001233111 | Esophagus | ESCC | regulation of apoptotic signaling pathway | 256/8552 | 356/18723 | 4.11e-24 | 1.04e-21 | 256 |
GO:2001242111 | Esophagus | ESCC | regulation of intrinsic apoptotic signaling pathway | 128/8552 | 164/18723 | 1.75e-17 | 1.50e-15 | 128 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ACKR3 | SNV | Missense_Mutation | | c.699C>A | p.Phe233Leu | p.F233L | P25106 | protein_coding | tolerated(0.51) | benign(0) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ACKR3 | SNV | Missense_Mutation | rs777382973 | c.1055C>T | p.Thr352Met | p.T352M | P25106 | protein_coding | tolerated(0.05) | benign(0.009) | TCGA-AP-A0LI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | SD |
ACKR3 | SNV | Missense_Mutation | novel | c.784N>A | p.Leu262Ile | p.L262I | P25106 | protein_coding | tolerated(0.08) | benign(0.285) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
ACKR3 | SNV | Missense_Mutation | novel | c.851C>A | p.Pro284His | p.P284H | P25106 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ACKR3 | SNV | Missense_Mutation | rs201643093 | c.722N>T | p.Ala241Val | p.A241V | P25106 | protein_coding | tolerated(0.44) | benign(0.063) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
ACKR3 | SNV | Missense_Mutation | rs558720877 | c.959N>A | p.Arg320His | p.R320H | P25106 | protein_coding | deleterious(0.01) | probably_damaging(0.959) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
ACKR3 | SNV | Missense_Mutation | novel | c.1081A>G | p.Thr361Ala | p.T361A | P25106 | protein_coding | tolerated(1) | benign(0) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
ACKR3 | SNV | Missense_Mutation | rs144999866 | c.347C>T | p.Thr116Met | p.T116M | P25106 | protein_coding | tolerated(0.25) | benign(0.336) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ACKR3 | SNV | Missense_Mutation | novel | c.54N>A | p.Ser18Arg | p.S18R | P25106 | protein_coding | tolerated(0.17) | benign(0.015) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ACKR3 | SNV | Missense_Mutation | novel | c.145N>A | p.Phe49Ile | p.F49I | P25106 | protein_coding | tolerated(1) | benign(0) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
57007 | ACKR3 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | agonist | 135652600 | | |
57007 | ACKR3 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | agonist | 135651708 | | |
57007 | ACKR3 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | agonist | 135649932 | PLERIXAFOR | |
57007 | ACKR3 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | agonist | 135651881 | | |